

6. 510(k) Summary

DEC 18 2008

6.	510(k) Summary	1
6.1.	Submitter Information	2
6.2.	Device Names, Predicate Device Names, and Predicate Device 510(k) Numbers:	2
6.3.	Statement of Identical Intended Use(s)/Indications:	3
6.4.	Principles of Operation and Technology:	3
6.5.	Design and Materials:	4
6.6.	Performance Evaluations:	4
6.7.	Substantial Equivalence Comparison:	4
6.7.1.	Intended Use:	4
6.7.2.	Principles of Operation and Technology:	4
6.7.3.	Design and Materials:	5
6.7.4.	Substantial Equivalence Summary:	5
6.8.	Additional Safety Information	5
6.9.	Conclusion	5

6.1. Submitter Information

510(k) Submitter: Terumo Cardiovascular Systems Corporation
 6200 Jackson Road,
 Ann Arbor, MI 48103

Primary Contact Name: Junko Kurosawa,
 Senior Associate, Regulatory Management
 Tel: 1(800)262-3304, Extension 6563
 Fax: (734)741-6030

Secondary Contact Name: Christina Thomas,
 Manager, Regulatory Management
 Tel: 1(800)262-3304, Extension 6278
 Fax: (734)741-6030

Date Prepared: November 7, 2008

6.2. Device Names, Predicate Device Names, and Predicate Device 510(k) Numbers:

Name of the Unmodified Device	510(k) Number of Sponsor's Unmodified Device	Clearance date	Name of the Modified Device
Terumo® Dual-Stage Venous Return Cannula	K920902	1993-05-11	X-coated Terumo® Dual-Stage Venous Return Cannula
Sarns™ Dual Stage Venous Return Catheters			X-coated Sarns™ Dual Stage Venous Return Catheters
Sarns™ Malleable Dual Stage Venous Return Catheters			X-coated Sarns™ Malleable Dual Stage Venous Return Catheters
Sarns™ Malleable Venous Return Catheters	K905224	1991-02-05	X-coated Sarns™ Malleable Venous Return Catheters
Sarns™ High Flow Aortic Arch Cannula	K770429	1977-03-16	X-coated Sarns™ High Flow Aortic Arch Cannula
Sarns™ Soft-Flow™ Extended Aortic Cannula	K934127	1994-02-22	X-coated Sarns™ Soft-Flow™ Extended Aortic Cannula

These devices are substantially equivalent in intended use, materials, design, technology, principles of operation, and performance.

6.3. Statement of Identical Intended Use(s)/Indications:

TCVS asserts that the intended use(s)/indications for the X-coated Terumo® Dual-Stage Venous Cannula are the same intended use(s)/indications that currently exist for the unmodified Terumo® Dual-Stage Venous Cannula.

TCVS asserts that the intended use(s)/indications for the X-coated Sarns™ Dual Stage Venous Return Catheters are the same intended use(s)/indications that currently exist for the unmodified Sarns™ Dual Stage Venous Return Catheters.

TCVS asserts that the intended use(s)/indications for the X-coated Sarns™ Malleable Venous Return Catheters are the same intended use(s)/indications that currently exist for the unmodified Sarns™ Malleable Venous Return Catheters.

TCVS asserts that the intended use(s)/indications for the X-coated Sarns™ Malleable Dual Stage Venous Return Catheters are the same intended use(s)/indications that currently exist for the unmodified Sarns™ Malleable Dual Stage Venous Return Catheters.

TCVS asserts that the intended use(s)/indications for the X-coated Sarns™ High Flow Aortic Arch Cannula are the same intended use(s)/indications that currently exist for the unmodified Sarns™ High Flow Aortic Arch Cannula.

TCVS asserts that the intended use(s)/indications for the X-coated Sarns™ Soft-Flow™ Extended Aortic Cannula are the same intended use(s)/indications that currently exist for the unmodified Sarns™ Soft-Flow™ Extended Aortic Cannula.

These devices are indicated for up to 6 hours of use.

6.4. Principles of Operation and Technology:

The X-coated venous and arterial cannulae discussed in this submission are used in open heart surgery.

During open heart surgery blood is drained into a venous cannula just upstream of the heart, at the superior / inferior vena cava and right atrium. The cannula is connected to tubing that routes the blood to a heart / lung machine where the blood is pumped and oxygenated. The blood then continues through this perfusion circuit back to the outlet side of the heart (the patient's aorta), where the blood re-enters the patient's circulatory system via the ascending aorta through an arterial cannulae. Platelets adhesion is reduced while blood travels through this circulatory path on the surface covered with X-coat polymer.

6.5. Design and Materials:

The design of cannulae and catheters is such that they meet their stated intended use, and provide an acceptable level of performance and safety to the patients. Except for the X-coat application, the design and material of the X-coated cannulae will remain the same as the unmodified cannulae. The X-coat application does not affect the cannulae design.

Venous and arterial cannulae contained in this submission are structured as straight, or slightly curved, flexible tubes which are inserted into the heart to circulate blood. Depending on the location of cannulation, size, and clinicians' preference, there is a range of design variations. These features include, but are not limited, wire reinforcement, various stylets used to help guide the cannula, tip formation (conical vs. angled), number of drainage baskets (two stage), luers, and connectors.

The generic materials for these cannulae will remain the same.

6.6. Performance Evaluations:

The performance of the X-coated Cannulae will remain the same as the unmodified cannulae. The X-coat application does not affect the functional cannulae performance. The X-coat application reduces the platelet adhesion.

The following performance evaluations of the cannulae were conducted to demonstrate its equivalence to the uncoated cannulae.

- Hemolysis
- Bond Strength
 - Leak testing
 - Pull strength testing
 - Flex testing
- Accelerated aging / Shelf life test

6.7. Substantial Equivalence Comparison:

6.7.1. Intended Use:

The intended use of the modified device will remain the same as the predicate device.

6.7.2. Principles of Operation and Technology:

The principle of operation & technology used in the modified device will remain the same as the predicate device.

6.7.3. Design and Materials:

The design and materials, except for the X-coat application, will remain the same.

6.7.4. Substantial Equivalence Summary:

In summary, the X-coated cannulae and the uncoated cannulae are substantially equivalent in intended use, principles of operation and technology, design, and performance. Any noted differences between the devices do not raise new issues of safety and effectiveness.

6.8. Additional Safety Information

- Sterilization conditions have been validated in accordance with AAMI guidelines to provide a Sterility Assurance Level (SAL) of 10^{-6} .
- Post-sterilization release for use will be determined in consideration of maximum Ethylene Oxide, Ethylene Chlorohydrin and Ethylene Glycol (as appropriate) residue limits and maximum levels of patient exposure in accordance with EN ISO 10993-7 and AAMI TIR-19.
- Biocompatibility studies were conducted using the same materials or combination of materials for predicate devices as recommended in the FDA General Program Memorandum #G95-1 (5/1/95): Use of International Standard ISO 10993: 2003, "Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing." [External Communicating Devices, Circulating Blood, Limited Exposure (≤ 24 hours) Contact Duration]. The blood contacting materials were found to be biocompatible.
- Terumo has conducted material characterization studies – including physio-chemical profiles of aged and non-aged devices to demonstrate stability of the materials, and found the materials to be stable over the expiry of the product.

6.9. Conclusion

In summary, the X-coated cannulae are substantially equivalent in intended use, principles of operation and technology, design and performance to the uncoated cannulae.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Terumo Cardiovascular Systems Corp.
c/o Mr. Junka Kurosawa
Senior Associate, Regulatory Management
6200 Jackson Rd.
Ann Arbor, MI 48103

DEC 18 2008

Re: K083301
X-coated Terumo® Dual-Stage Venous Return Cannula,
X-coated Sarns™ Dual-Stage Venous Return Catheters
X-coated Sarns™ Malleable Venous Return Catheters,
X-coated Sarns™ Malleable Dual-Stage Venous Return Catheters,
X-coated Sarns™ High Flow Aortic Arch Cannula,
X-coated Sarns™ Soft-Flow™ Extended Aortic Cannula
Regulation Number: 21 CFR 870.4210
Regulation Name: Cardiopulmonary bypass vascular catheter, cannula, or tubing
Regulatory Class: Class II (two)
Product Code: DWF
Dated: November 7, 2008
Received: November 18, 2008

Dear Mr. Kurosawa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.



If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device

can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K083301

Device Name: X-coated Terumo® Dual-Stage Venous Return Cannula.
X-coated Sarns™ Dual-Stage Venous Return Catheters
X-coated Sarns™ Malleable Venous Return Catheters.
X-coated Sarns™ Malleable Dual-Stage Venous Return Catheters.
X-coated Sarns™ High Flow Aortic Arch Cannula.
X-coated Sarns™ Soft-Flow™ Extended Aortic Cannula.

Indications For Use:

The X-coating is intended to reduce the adhesion of platelets to the blood contacting surfaces of the device during cardiopulmonary bypass procedures.

The X-coated Terumo® Dual-Stage Venous Return Cannula is indicated for use for adult single tube blood drainage from the right atrium and inferior vena cava (IVC) and delivery of the blood to the extracorporeal circuit during cardiopulmonary bypass.

The X-coated Sarns™ Dual-Stage Venous Return Catheters are indicated for single tube venous drainage from the right atrium and vena cava during cardiopulmonary bypass surgery.

The Sarns™ Malleable Venous Return Catheters are indicated for venous drainage during cardiopulmonary bypass surgery: the 24, 28, 30, 32, 34, 36 and 40 Fr. are for dual cannulation of the superior and inferior vena cava; the 40 Fr. is for single cannulation of the right atrium.

The X-coated Sarns™ Malleable Dual-Stage Venous Return Catheters are indicated for single-tube venous drainage from the right atrium and vena cava during cardiopulmonary bypass surgery.

The X-coated Sarns™ High Flow Aortic Arch Cannula is indicated for use in perfusion of the ascending aorta during cardiopulmonary bypass surgery.

The X-coated Sarns™ Soft-Flow™ Extended Aortic Cannula is indicated for use in perfusion of the ascending aorta during cardiopulmonary bypass surgery.

These devices are indicated for up to 6 hours of use.

Prescription Use X OR Over-The-Counter Use

(Per 21 CFR 801.109)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Dennis R. Kuchner
(Division Sign-Off)
Division of Cardiovascular Devices

510(k) Number K083301